KG
KNSA icon

Kilter Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Kilter Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9K Hold
61
– – ﹤0.01% 756
2026
Q1 		$2.94K Hold
61
– – ﹤0.01% 800
2025
Q4 		$2.52K Hold
61
– – ﹤0.01% 690
2025
Q3 		$2.37K Hold
61
– – ﹤0.01% 615
2025
Q2 		$1.69K Buy
+61
New +$1.55K ﹤0.01% 670

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Kilter Group's KNSA Position: Q2 2026 in Review

Kilter Group held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2026 at 61 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Kilter Group first reported a position in KNSA in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Kilter Group held 61 shares of Kiniksa Pharmaceuticals worth $3.9K as of Q2 2026.
  • Kilter Group left its Kiniksa Pharmaceuticals share count unchanged in Q2 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #756 holding.
  • Kilter Group first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.